ArticleNeurochemical research2010
Intranasal administration of nerve growth factor produces antidepressant-like effects in animals.
Article in Neurochemical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.MedComm · 2025Review
- Review
- Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients.Pharmaceutics · 2022Review
- Intranasal Delivery of Nerve Growth Factor in Neurodegenerative Diseases and Neurotrauma.Frontiers in pharmacology · 2021Review
- Evaluation of stress status using the stress map for guide dog candidates in the training stage using variations in the serum cortisol with nerve growth factor and magnesium ions.Veterinary and animal science · 2020Article
- Depression and Cardiovascular Disease: The Viewpoint of Platelets.International journal of molecular sciences · 2020Review
- Single Administration of HBK-15-a Triple 5-HTMolecular neurobiology · 2018Article
- HSP105 prevents depression-like behavior by increasing hippocampal brain-derived neurotrophic factor levels in mice.Science advances · 2017Article
- Calcitonin gene-related peptide pre-administration acts as a novel antidepressant in stressed mice.Scientific reports · 2015Article
- Time Course of Behavioral Alteration and mRNA Levels of Neurotrophic Factor Following Stress Exposure in Mouse.Cellular and molecular neurobiology · 2015Article
- Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles.Protein and peptide letters · 2014Review
- Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses.Frontiers in cellular neuroscience · 2013Article
- Neurobiology of chronic mild stress: parallels to major depression.Neuroscience and biobehavioral reviews · 2012Review
- Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- Neurotrophins role in depression neurobiology: a review of basic and clinical evidence.Current neuropharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many works showed that nerve growth factor (NGF) injected into the brain of animal model emerges potential antidepressant effects. However, this route of administration significantly restricts the application of NGF clinically. Here, we reported that intranasal NGF could provide an alternative to intraventricular injection. The behavioral analysis showed that intranasal administration of NGF reduced the immobility time in forced swimming test (FST) and tail suspension test (TST) in mice. Likewise, intranasal NGF increased the sucrose intake and the locomotor activity in rats after unpredictable chronic mild stress (UCMS). Furthermore, intranasal NGF increased the levels of monoamine neurotransmitters (norepinephrine, dopamine) in the frontal cortex and hippocampus and affected the number of 5-bromodeoxyuridine (BrdU), c-fos and caspase-3 positive neurons in dentate gyrus of hippocampus in rats after UCMS. In summary, intranasal NGF had significant antidepressant effects on animal models of depression and this route of administration may provide a promising way to deliver NGF to brain in a therapeutic perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.